Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTD1801 in Adults With NASH and T2DM
NCT03656744Phase 2Completed
- Sponsor
- HighTide Therapeutics, Inc.
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of berberine ursodeoxycholate in Nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by HighTide Therapeutics, Inc. Primary endpoint: Absolute Change in Liver Fat Content as Measured by MRI-PDFF at 18 weeks. Started Nov 2018; status: completed.
02
Drugs
berberine ursodeoxycholate
03
Conditions
Nonalcoholic steatohepatitis (NASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03656744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656744.